Delivery Order V797D70252-36C26025F0134
Award Date
1/23/25
Potential Completion Date
2/15/25
Potential Value
$2.5K
Federal Agency
Veterans Integrated Service Network 20
Awardee
Gilead Sciences Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Dublin, OH 43017, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Veterans Integrated Service Network 21 (VISN 21), which is part of the U.S. Department of Veterans Affairs (VA), to Gilead Sciences Inc. The contract is for the pharmaceutical product Lenacapavir (Sunlenca), which is used to treat HIV. The contract has a firm fixed price of $14,894.47 and a period of performance ending on July 14, 2025. The contract was awarded on May 14, 2025 and is not set aside for small businesses. Gilead Sciences Inc. is a...
This is a $47,796.92 firm-fixed-price delivery order awarded to Gilead Sciences Inc. (Gilead) by the U.S. Department of Veterans Affairs (VA) for the pharmaceutical product LENACAPAVIR. The order was placed under Gilead's General Services Administration (GSA) Schedule 61-IB contract for Pharmaceuticals and Drugs. Gilead is a biopharmaceutical company that provides a range of critical medications to federal agencies, including antiviral treatments, cancer immunotherapies, and pulmonary...
This federal contract award is for the delivery of SULENCA INJ, a pharmaceutical product, to the U.S. Department of Veterans Affairs (VA) through Gilead Sciences Inc., the prime contractor. The contract has a ceiling value of $14,937.69 and was awarded on September 12, 2024 as a firm-fixed-price delivery order under Gilead's General Services Administration (GSA) Schedule contract for Pharmaceuticals and Drugs (FSS-61-IB). The contract has an ultimate completion date of September 13, 2024 and was...
This is a firm fixed-price delivery order awarded by the Department of Veterans Affairs (VA) to Gilead Sciences Inc., doing business as Gilead, a biopharmaceutical company. The $47,796.92 award is for the supply of the HIV medication Lenacapavir in tablet and injection forms. The contract is issued under Gilead's GSA Schedule 61-IB for Pharmaceuticals and Drugs and does not have a set-aside designation. Gilead provides pharmaceuticals directly to the VA without any subcontractors. This award...
This is a delivery order contract awarded by the Department of Veterans Affairs to Gilead Sciences Inc. to provide Veklury (remdesivir) for COVID-19 treatment. The contract has a firm fixed price of $155,700.00 and a completion date of January 31, 2021. Gilead is a biopharmaceutical company that provides pharmaceuticals and biologics to government customers through its GSA Schedule contract. Gilead has received numerous federal contracts from the VA to supply antiviral and oncology...
This is a federal delivery order contract awarded by the Veterans Integrated Service Network (VISN) 16 of the U.S. Department of Veterans Affairs (VA) to Gilead Sciences Inc., a large biopharmaceutical company. The contract is for the supply of Veklury (remdesivir), a COVID-19 treatment medication. The contract has a ceiling value of $77,850.00 and was awarded on December 23, 2020, with a completion date of January 22, 2021. The contract was awarded under GSA Schedule 61-IB for Pharmaceuticals...
This is a federal contract awarded by the U.S. Department of Veterans Affairs (VA) to Gilead Sciences Inc. (Gilead), a prominent biopharmaceutical company. The contract, valued at $307,511.22, is a delivery order under Gilead's General Services Administration (GSA) Schedule 61-IB for Pharmaceuticals and Drugs. It provides the VA's Veterans Integrated Service Network (VISN) with the cancer immunotherapy drug YESCARTA. The contract has an ultimate completion date of October 31, 2023. Gilead is the...
This is a delivery order awarded by the Department of Veterans Affairs (VA) Veterans Health Administration to Gilead Sciences Inc., a biopharmaceutical company, for the supply of the COVID-19 antiviral medication Veklury (remdesivir). The order has a firm-fixed price of $155,700.00 and a completion date of October 29, 2021. The contract was awarded on December 9, 2020 and is placed under Gilead's existing General Services Administration (GSA) Multiple Award Schedule contract for...
The Department of Veterans Affairs (VA) Veterans Health Administration awarded Gilead Sciences Inc. a $136,237.50 firm-fixed-price delivery order contract for Veklury (remdesivir), a COVID-19 treatment. This order was placed against Gilead's existing Multiple Award Schedule (MAS) contract for Pharmaceuticals and Drugs (FSS-61-IB). Gilead, a biopharmaceutical company, is the prime contractor and will directly provide the medication, with performance taking place in Foster City, California. This...
This is a delivery order under the GSA Schedule 61-IB for Pharmaceuticals and Drugs, awarded by the U.S. Department of Veterans Affairs (VA) to Gilead Sciences Inc. (Gilead) for the COVID-19 treatment Veklury (remdesivir). The $77,850 fixed-price contract has a performance period ending on March 31, 2021. Gilead, a large biopharmaceutical company, is the sole-source manufacturer of Veklury and a key supplier of critical medications to federal healthcare programs, particularly the VA. The...